Investigational drug · Phase 2
AG-120
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Leukemia, Myeloid, Acute.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
68
Any phase or sponsor naming "AG-120"
First trial start
2016
Jun 3, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AG-120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Leukemia, Myeloid, Acute
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "AG-120" as an intervention, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
National Cancer Institute (NCI)NIH
NCT03155620 · 1,377 participants · Start Jul 31, 2017 · Primary completion Mar 31, 2025
Drug: Ensartinib; Erdafitinib and 11 more · For: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 172 sites in all
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerPivotal-lookingNot yet recruiting
UNICANCERAcademic, hospital or other
NCT07745296 · 990 participants (planned) · Start Jan 2, 2027 · Primary completion Jul 2, 2033
Drug: Futibatinib; Ivosidenib + Capecitabine and 2 more · For: Biliary Tract Cancer (BTC)
- A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyPivotal-lookingActive, not recruiting
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT03839771 · 968 participants (planned) · Start Mar 1, 2019 · Primary completion Apr 17, 2027
Drug: AG-120; Placebo for AG-120 and 2 more · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
Sites: Adelaide, Australia; Brisbane, Australia; Camperdown, Australia · 181 sites in all
- Personalized Medicine for Advanced Biliary Cancer PatientsPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT05615818 · 800 participants (planned) · Start Jul 18, 2024 · Primary completion Jun 2027
Drug: Futibatinib; Ivosidenib and 8 more · For: Biliary Tract Neoplasms
Sites: Brussels, Belgium; Edegem, Belgium; Leuven, Belgium · 69 sites in all
- MRD-positive AML Clinical StudyPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07131059 · 537 participants (planned) · Start May 11, 2024 · Primary completion May 10, 2028
Drug: Ivosidenib; Gilteritinib and 10 more · For: AML, Adult
Sites: Tianjin, China
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SitePivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03498521 · 529 participants · Start Jul 10, 2018 · Primary completion Feb 14, 2023
Drug: Alectinib; Vismodegib and 16 more · For: Cancer of Unknown Primary Site
Sites: Blacktown, Australia; St Leonards, Australia; South Brisbane, Australia · 125 sites in all
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT06265545 · 458 participants (planned) · Start Feb 22, 2024 · Primary completion Jan 30, 2028
Drug: Ivosidenib; Venetoclax and 7 more · For: AML; Refractory; Relapsed
Sites: Tianjin, China
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.Pivotal-lookingRecruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSAcademic, hospital or other
NCT06713837 · 339 participants (planned) · Start Feb 27, 2025 · Primary completion Jan 2028
Drug: High intensity therapies; Low intensity therapies · For: Acute Myeloid Leukemia; Relapse/Recurrence
Sites: Brno, Czechia; Hradec Králové, Czechia; Olomouc, Czechia · 51 sites in all
Peking Union Medical College HospitalAcademic, hospital or other
NCT07282262 · 300 participants (planned) · Start May 1, 2024 · Primary completion Oct 1, 2026
Drug: Ivosidenib; Lenvatinib and 1 more · For: Biliary Tract Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Methods for assessing binding of a small-molecule radioligand to soluble enzyme isocitrate dehydrogenase 1 variants.
Deuther-Conrad W, Lai TH, Maurer A, et al. · EJNMMI Radiopharm Chem 2026
- Bayesian active learning-aided structure-based virtual screening reveals novel inhibitors of mutant IDH1.
Xu S, Yang Y, Chen C, et al. · Mol Divers 2026
- Multiplexed Data-Independent Acquisition (mDIA) to Profile Extracellular Vesicle Proteomes.
Liu YK, Miller N, Hadisurya M, et al. · Mol Cell Proteomics 2026
- State of the Art of IDH Inhibitors: Emerging Questions and Perspectives.
de Lima JAL, Lima LM · Anticancer Agents Med Chem 2026
- Multiplexed Data-Independent Acquisition (mDIA) to Profile Extracellular Vesicle Proteomes.
Liu YK, Miller N, Hadisurya M, et al. · bioRxiv 2025
- Reviewing the IDH1 Mutation-Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies.
Wang Y, Bai H, Wang A, et al. · Chem Biol Drug Des 2025
Also in development for Leukemia, Myeloid, Acute
- BleximenibJNJ-75276617Phase 32 trials
Johnson & Johnson (Janssen) · Acute Leukemia, Leukemia, Myeloid, Acute
- CusatuzumabOV-1001, JNJ-74494550Phase 22 trials
OncoVerity, Inc. · Leukemia, Myeloid, Acute
- AG-221Phase 21 trial
Bristol Myers Squibb · Leukemia, Myeloid, Acute
- BG1805Phase 21 trial
Guangzhou Bio-gene Technology Co., Ltd · Leukemia, Myeloid, Acute
- TuspetinibHM43239Phase 21 trial
Aptose Biosciences Inc. · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.